Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Capital Employed: 2022-2025

Historic Return on Capital Employed for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -0.30%.

  • Entrada Therapeutics' Return on Capital Employed fell 41.00% to -0.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.30%, marking a year-over-year decrease of 41.00%. This contributed to the annual value of 0.10% for FY2024, which is 12.00% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Return on Capital Employed stood at -0.30%, which was down 39.15% from -0.21% recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Return on Capital Employed ranged from a high of 0.20% in Q2 2024 and a low of -0.40% during Q4 2022.
  • Its 3-year average for Return on Capital Employed is -0.06%, with a median of -0.01% in 2023.
  • In the last 5 years, Entrada Therapeutics' Return on Capital Employed surged by 45bps in 2024 and then slumped by 42bps in 2025.
  • Over the past 4 years, Entrada Therapeutics' Return on Capital Employed (Quarterly) stood at -0.40% in 2022, then skyrocketed by 39bps to -0.01% in 2023, then increased by 10bps to 0.09% in 2024, then plummeted by 41bps to -0.30% in 2025.
  • Its Return on Capital Employed stands at -0.30% for Q3 2025, versus -0.21% for Q2 2025 and 0.01% for Q1 2025.